Introduction: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.
introduction
Acute promyelocytic leukemia (APL) is a well-defined subtype of leukemia with specific and peculiar characteristics. The most important characteristic of this disease is translocation between chromosomes 15 and 17 in leukemic cells and the presence of PML/RARA fusion gene product in affected cells [1] .
Today, accepted protocols for treatment of APL contain all-trans retinoic acid (ATRA), which is usually combined with an antracycline. Overall survival and 2-4 year event-free survival are 70-80% and 55-85%, respectively [2] [3] [4] [5] [6] [7] [8] [9] [10] . Maintenance therapy by ATRA with or without low-dose chemotherapy improves the results and reduces the relapse rate [6, 8, 11] .
Recently, some groups observed that an ancient drug, arsenic trioxide, is useful for treatment of resistant or relapsed cases of APL after treatment with ATRA [12] [13] [14] [15] . Arsenic trioxide is the most active single agent against APL cells, which induces maturation and apoptosis in APL cells [1] and reduces microvascular density of bone marrow.
Soignet et al. [16] showed that arsenic trioxide could induce a high molecular remission rate in relapsed APL cases. Today arsenic trioxide is accepted for treatment of such cases and has improved the results of treatment of APL, which is comparable to stem cell transplantation [17] . The role of this drug in the induction of remission or consolidation phase of new cases of APL is less clear.
The purpose of our study is to define the efficiency and the safety of arsenic trioxide in the treatment of new cases of APL and their follow-up.
materials and methods
Acute promyelocytic leukemia diagnosed by clinical manifestations, morphologic FAB criteria, cytogenetics or fluorescence in situ hybridization study for detection of t (15, 17) and/or RT-PCR for PML-RARA transcript.
Between May 2000 and January 2005, 111 APL patients were enrolled in our study. Pregnant women and patients with severe renal, hepatic or cardiac dysfunction (creatinine >2 mg/dl, billirubin >5 mg/dl and ejection fraction <50%), and patients with intracranial hemmorhage at presentation, were excluded from this study.
Seventeen patients were relapsed and 94 were new cases. Three patients had relapsed after previous stem cell transplantation (one after allogeneic and two after autologous stem cell transplantation) and 14 patients had relapsed after previous treatment by ATRA and chemotherapy. None of the relapsed cases had used ATRA or chemotherapy for maintenance therapy.
Hematological values and clinical characteristics of patients are shown in Table 1 . Arsenic trioxide was prepared as 10 mg/10 ml vials, manufactured by the pharmaceutical faculty of Tehran University of Medical Sciences and was approved by the Deputy of Food and Drugs of the Ministry of Health and Medical Education for this clinical trial.
This clinical trial was approved by a local ethics review board and consent forms were obtained before treatment.
induction of remission
After diagnosis of APL according to above criteria, arsenic trioxide was started immediately as a 2-h intravenous infusion of 0.15 mg/kg in 500 ml dextrose water. Treatment continued until achievement of complete remission by morphologic criteria or to a maximum of 60 days. Also, we did not use any chemotherapeutic agents or leukopheresis during treatment.
supportive care during treatment
Prothrombine time, activated partial thromboplastin time, fibrin degradation products, and fibrinogen were measured at the time of diagnosis and regularly during the treatment. In the presence of disseminated intravscular coagulopathy, fresh frozen plasma and platelets were transfused.
White blood cell counts and peripheral blood smears were observed daily. Liver and renal functions were assessed regularly and fasting blood sugar, sodium, potassium, calcium, magnesium and urine analysis were tested twice weekly. Electrocardiograms were studied every other day and QTc intervals measured. In case of prolonged QTc, magnesium and potassium were infused for correction of QTc. Patients' weight was measured daily and diuretics prescribed for severe edema or weight gain. If the liver enzymes increased to >10 times the upper limit of normal, or bilirubin to >5 mg/dl or creatinin to >2 mg/dl, arsenic trioxide was discontinued for several days. After correction of any abnormalities, drug administration was restarted with half of original dose and rapidly increased to full dose. In cases with hepatic or renal complications or APL differentiation syndrome during induction of remission phase, a full dose of arsenic trioxide was used as the consolidation phase, without any significant complications.
APL differentiation syndrome (defined as weight gain, fever, polyserositis and dyspnea with or without radiographic markers of pulmonary infiltration) was treated by dexamethasone 10 mg twice daily, until patients' symptoms improved. For patients whose APL differentiation syndrome progressed to adult respiratory distress syndrome or pulmonary hemorrhage, we immediately used assisted ventilation with oxygen supplement and activated factor seven (Novo seven Ò ) for some patients. Peripheral blood smears were observed daily and bone marrow studied every 10 days for remission and maturation evaluation.
After complete remission was achieved, treatment was discontinued and patients discharged.
consolidation therapy
After 28 days rest, consolidation therapy was started. It consisted of outpatient infusion of arsenic trioxide at daily dose of 0.15 mg/kg, 6 days a week, for a total of 28 infusions. During this period, patients visited every week and complete blood count (CBC), liver enzymes, renal function and electrocardiogram were evaluated.
follow-up
After consolidation therapy, patients visited every month and then every 3 months. At each visit, their CBC, liver and renal function were studied.
definition of outcome
Complete remission was defined using the classic definition: neutrophil count >1500/mm 3 , platelet count >100 000/mm 3 and immature cells (promyelocytes and myeloblast) <5% of nucleated bone marrow cells. Disease-free survival was measured from the time of complete remission until relapse or censorship of patients' data. Overall survival was measured from the time of diagnosis and beginning of treatment by arsenic trioxide until the time of death or censorship of patients' data.
minimal residual disease
After complete remission, 48 patients evaluated for minimal residual disease (MRD). RT-PCR studies were performed on peripheral blood samples, searching for mRNA of PML-_RARA isoforms. MRD was studied after the consolidation phase and 12 months after complete remission. Sensitivity of RT-PCR was 10 ÿ3 for MRD detection. Sequences of forward and reverse primers are shown in Table 2 .
statistical analysis
Median values were measured for complete remission and hospitalization time. Disease-free and overall survival were calculated using the KaplanMeier method. Importance of risk factors for relapse and survival (including age, sex, white blood cell count at presentation, APL differentiation syndrome, hyperleukocytosis, treatment as new case versus relapsed cases, and MRD status) calculated by Fisher's exact test, log-rank test and logistic regression.
results complete remission
Complete remission was observed in 95 patients (85.6%). The median time for complete remission was 30 days (range 20-43). hyperleukocytosis Median white blood cell count was 2050/mm 3 at the time of diagnosis. In 18 patients (16.2%) white blood cell count was >10 000/mm 3 . Hyperleukocytosis (white blood cell count >10 000/mm 3 ) occurred in 65 patients (58.6%) during treatment. The median day for the beginning of hyperleukocytosis was 10 days (range 2-22) after starting treatment and the median highest leukocyte count in this group was 49 500/mm 3 (range 10 200-167 700). There was no significant difference in white blood cell count at disease onset between patients with and without hyperleukocytosis, and it did not increase early mortality of treatment. We did not observe any association between hyperleukocytosis and APL differentiation syndrome, remission rate and relapse rate. Overall and disease-free survival were not significantly different for patients with and without hyperleukocytosis.
APL differentiation syndrome
APL differentiation syndrome usually maifested as weight gain, fever and respiratory distress, and in fatal cases rapidly terminated in pulmonary hemorrhage and respiratory failure. This complication was observed in 23 patients (20.7%); 10 of them succumbed during this complication (eight died due to APL differentiation syndrome and respiratory failure, one due to brain and pulmonary aspergilosis after resolution of APL differentiation syndrome and one due to intracranial hemorrhage).
There was no difference between new cases and relapsed subgroups. The death rate was significantly higher in patients with APL differentiation syndrome (P < 0.006) disease-free and overall survival analysis Median time of follow-up was 16.5 months (range 1-57). Relapse was observed in 24 patients (25.3%) in complete remission and median time of relapse after first complete remission was 17 months. One-and 2-year disease-free survival for patients in complete remission was 88.3% and 63.7%, respectively.
Disease-free survival was the same in new cases and patients who were treated after relapse following previous ATRA and chemotherapy.
For patients who relapsed after the first course of arsenic trioxide treatment, treatment was restarted with arsenic trioxide with the same schedule as the first treatment. Nineteen complete remissions observed in this group (79.2%) and median time of relapse for this group was 18 months.
One-and 3-year survival for patients in complete remission were 94.5% and 87.6%, respectively (Figure 1) . Survival was the same in new cases of acute promyelocytic leukaemia and patients who treated after relapse following previous ATRA and chemotherapy.
We could not find any independent risk factor for relapse and survival in complete remission patients, except positive MRD following consolidation or during follow-up (P = 0.01 and <0.0001 respectively).
molecular follow-up of patients
Forty-eight patients were followed up by semi-sensitive RT-PCR for detection of PML-RARA fusion gene mRNA during the first year after complete remission.
All patients were in complete hematological remission at the time of MRD assessment. RT-PCR was positive in four patients (8.3%), three of whom relapsed clinically.
retreatment of relapse
Twenty-four patients who relapsed were retreated with the same treatment (arsenic trioxide) as before. Again, we observed 19 complete remissions (79.2%), and five patients died during second remission induction by arsenic trioxide.
discussion
We suggest that the complete remission rate of new cases of APL treated by arsenic trioxide is comparable to an ATRA-chemotherapy regimen.
In European APL study group experience, event-free survival was 84% for patients who were treated by concomitant chemotherapy and ATRA and 77% for patients on a sequential regimen [18] .
With arsenic trioxide alone, overall survival and complete remission rates were comparable to those of the European group study, although we suggest that adding maintenance therapy by intermittent infusion of arsenic trioxide with or without oral chemotherapy, or adding chemotherapy to induction or consolidation phase, may improve results. Recently, we increased the consolidation phase of arsenic trioxide to four 
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cycles (two cycles after complete remission, and one 1 year and 2 years after complete remission, to reduce relapse rate).
ATRA without chemotherapy could not induce a durable remission [19] [20] [21] [22] , so we suggest that arsenic trioxide is superior to ATRA for new cases and can induce a durable remission and good disease-free survival. Also, long-term treatment with ATRA can induce drug metabolism in the liver, which reduces its efficiency. So possibly, arsenic trioxide would be part of frontline regimen in future.
In APL patients treated with arsenic trioxide, the most important limitation was APL differentiation syndrome, which is sometimes fatal. Although it is possible to control this complication by corticosteroids, better supportive care and use of activated factor seven in patients with pulmonary hemorrhage, it is sometimes fatal. This should be a subject for future studies to control this complication by early chemotherapy, use of ATRA in combination with arsenic trioxide and improved supportive care. Detection of MRD is another possible subject for study to improve the results of treatment and to start arsenic trioxide early for these patients. It has been shown that if MRD is negative twice after complete remission, risk of relapse is minimal [5, 23, 24] . By a more sensitive RT-PCR (10 ÿ4 versus 10 ÿ3 in our study) after induction phase, Soignet et al. [16] observed that 85% of patients were negative for MRD. In our study, MRD was negative in 91.7% of patients for 1 year after complete remission.
Also, we suggest that early treatment after detection of MRD may improve the results of arsenic trioxide therapy and may prevent high mortality of relapse [25] [26] [27] .
Recently, we completed a study on patients' samples by a sensitive quantitative real-time PCR every 3 months, and we could define a threshold for relapse (unpublished data), which will be useful for early detection and treatment to improve results. We suggest that quantitative PCR is more accurate and predictive than regular PCR, and should be repeated for each patients at regular intervals (at least every 3 months, during first 2-3 years after remission) to predict relapse and early treatment. 
